Na+/H+ exchange inhibition attenuates left ventricular remodeling and preserves systolic function in

Giuseppe Marano1, Alessandro Vergari, Liviana Catalano

  • 1Laboratorio di Farmacologia, Istituto Superiore di Sanità, Viale Regina Elena 299, Rome, Italy. gmarano@iss.it

Insights

Inhibiting the Na+/H+ exchanger isoform 1 (NHE-1) with cariporide prevented cardiac hypertrophy and preserved left ventricular function in mice subjected to pressure overload. This suggests NHE-1 is a key target for treating heart failure.

Area of Science:

  • Cardiovascular Physiology
  • Pharmacology
  • Cardiac Remodeling

Background:

  • Cardiac hypertrophy is a response to increased afterload.
  • Na+/H+ exchanger (NHE) inhibition shows promise in animal models for reducing cardiac hypertrophy and mitigating myocardial infarction.
  • The role of NHE isoform 1 (NHE-1) in left ventricular (LV) function under chronic pressure overload requires further investigation.

Purpose of the Study:

  • To investigate the chronic effects of cariporide, a selective NHE-1 inhibitor, on left ventricular systolic and diastolic function.
  • To assess the impact of NHE-1 inhibition on cardiac hypertrophy and remodeling induced by pressure overload.

Main Methods:

  • Male CD-1 mice underwent thoracic aortic banding to induce cardiac pressure overload.
  • Mice received either a control diet or a diet supplemented with cariporide (6000 p.p.m.).
  • Echocardiography and cardiac catheterization were used to assess LV dimensions, systolic, and diastolic function at 2 and 5 weeks post-surgery. Histological analysis was also performed.

Main Results:

  • Cariporide treatment significantly attenuated left ventricular hypertrophy (LVH) and preserved systolic function and contractility in banded mice compared to vehicle-treated controls at both 2 and 5 weeks.
  • While diastolic function was not significantly different, cariporide prevented the LV chamber enlargement and systolic dysfunction observed in vehicle-treated banded mice at 5 weeks.
  • Histological analysis revealed that cariporide reduced cardiomyocyte hypertrophy but did not affect myocardial fibrosis in banded mice.

Conclusions:

  • The hypertrophic response to pressure overload is dependent on Na+/H+ exchanger isoform 1 (NHE-1) activity.
  • Chronic inhibition of NHE-1 with cariporide effectively prevents the deterioration of left ventricular performance during pressure overload.
  • NHE-1 inhibition represents a potential therapeutic strategy for managing cardiac hypertrophy and preventing heart failure progression.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...